It’s all about the US for Jens Bager & Co.

The US is going to be the major driving force for ALK-Abello’s growth in coming years, but the company is also working with several models for penetrating the markets in China, Brazil and Russia.

Foto: Carsten Bundgaard

Simplify, Innovate, Grow - those are the headlines in the strategy Danish allergy vaccine manufacturer ALK-Abello revealed last fall, and while a plan has been put in place for the two first points it is still uncertain if and how ALK will be able to perform in regards to the growth agenda.

One thing is certain, however; the company expects a sizeable contribution to its stagnating top line from Japan and especially the US. The partners on these markets, Torii and Merck, are currently trying to win approval to market tablets for the treatment of grass pollen and ragweed allergy – the latter only in the US.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch


Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier